The crosstalk of mTOR/S6K1 and Hedgehog pathways.

[1]  F. D. de Sauvage,et al.  Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. , 2011, Cancer research.

[2]  T. Curran,et al.  The Hedgehog's tale: developing strategies for targeting cancer , 2011, Nature Reviews Cancer.

[3]  J. Dufour,et al.  Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma , 2011, Molecular Cancer Therapeutics.

[4]  J. Manola,et al.  Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors , 2010, Clinical Cancer Research.

[5]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[6]  William Pao,et al.  Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[8]  A. Zask,et al.  Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. , 2010, Current opinion in drug discovery & development.

[9]  Paula Chaves,et al.  Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. , 2010, Journal of the National Cancer Institute.

[10]  M. Katoh,et al.  Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. , 2009, Current molecular medicine.

[11]  A. Lockhart,et al.  Novel targets in esophageal and gastric cancer: beyond antiangiogenesis , 2009, Expert opinion on investigational drugs.

[12]  Takao Kawabe,et al.  Regulation of the hedgehog signaling by the mitogen‐activated protein kinase cascade in gastric cancer , 2009, Molecular carcinogenesis.

[13]  J. Merchant,et al.  Paracrine Hedgehog signaling in stomach and intestine: new roles for hedgehog in gastrointestinal patterning. , 2009, Gastroenterology.

[14]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[15]  M. Katoh,et al.  Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. , 2009, International journal of oncology.

[16]  D. Jenkins.  Hedgehog signalling: emerging evidence for non-canonical pathways. , 2009, Cellular signalling.

[17]  F. D. de Sauvage,et al.  Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. , 2009, Trends in pharmacological sciences.

[18]  S. Sleijfer,et al.  The applicability of mTOR inhibition in solid tumors. , 2009, Current cancer drug targets.

[19]  M. Hongo,et al.  Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity , 2009, Journal of gastroenterology and hepatology.

[20]  J. Ajani,et al.  Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Kenneth K Wang,et al.  Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. , 2008, Cancer research.

[22]  Burton B. Yang,et al.  MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression , 2007, Proceedings of the National Academy of Sciences.

[23]  P. Hainaut,et al.  Esophageal cancer: The precursors (Part II) , 2007 .

[24]  G. Hortobagyi,et al.  IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway , 2007, Cell.

[25]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[26]  P. Hainaut,et al.  Esophageal cancer: Cases and causes (Part I) , 2007, Endoscopy.

[27]  Barbara Stecca,et al.  Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways , 2007, Proceedings of the National Academy of Sciences.

[28]  M. Katoh,et al.  Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). , 2006, International journal of molecular medicine.

[29]  I. Screpanti,et al.  Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination , 2006, Nature Cell Biology.

[30]  J. Ajani,et al.  Hedgehog: an Attribute to Tumor Regrowth after Chemoradiotherapy and a Target to Improve Radiation Response , 2006, Clinical Cancer Research.

[31]  T. Ochiya,et al.  Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. , 2006, Gastroenterology.

[32]  Steven P. Gygi,et al.  mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.

[33]  K. Caca,et al.  Molecularly targeted therapy for gastrointestinal cancer. , 2005, Current cancer drug targets.

[34]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[35]  Yutaka Shimada,et al.  Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours , 2003, Nature.

[36]  P. Ingham,et al.  Hedgehog signaling in animal development: paradigms and principles. , 2001, Genes & development.

[37]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Jankowski,et al.  Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFα , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[39]  M. Nakafuku,et al.  A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. , 1997, Development.

[40]  Lee F. Peng,et al.  Small-molecule modulators of the Sonic Hedgehog signaling pathway. , 2010, Molecular bioSystems.

[41]  Gerald C. Chu,et al.  GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. , 2009, Genes & development.

[42]  Steven Y. Cheng,et al.  Role and regulation of human tumor suppressor SUFU in Hedgehog signaling. , 2008, Advances in cancer research.

[43]  W. Bushman.  Hedgehog Signaling in Development and Cancer , 2007 .

[44]  S. Schreiber,et al.  Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.